Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

950

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Diabetes Mellitus, Type 2

Interventions

DRUG: Maridebart Cafraglutide
DRUG: Placebo

Sponsor

Amgen